[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nicotine-use-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nicotine-use-disorder":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,47,71,123,154,191,218,244,265,293],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100453234","phase-2-pharmaceutically-enhanced-reinforcement-for-reduced-alcohol-and-smoking-100453234",false,"NCT05181891","Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking","PERRAS","Inclusion Criteria:\n\n1. 4 or more standard drinks on the same occasion for women (5 or more standard drinks on the same occasion for men) on at least 4 occasions in the prior 30 days\n2. Seeking AUD treatment\n3. Seeking smoking cessation treatment\n4. Aged 18+ years\n5. DSM-5 diagnosis of AUD\n6. Currently smoking daily according to PhenX Smoking Status (100 or more lifetime cigarettes plus current daily smoking)\n7. Ability to read and speak English\n8. Ability to provide written informed consent\n9. Breath alcohol of 0.00 during informed consent\n10. Provision of at least 1 EtG-positive urine test at any time during the induction period and at least one COT-positive urine test at any time during the induction period; and\n11. Attended at least 4 of 6 possible visits during the induction period.\n\nExclusion Criteria:\n\n1. Significant risk of dangerous alcohol withdrawal, defined as a history of alcohol detoxification or seizure in the last 12 months and expression of concern by the participant about dangerous withdrawal\n2. Currently receiving any pharmacotherapy for alcohol\n3. Currently receiving any pharmacotherapy for smoking\n4. No suicide attempt in the last 20 years and\n5. Any other medical (discernable by initial blood tests) or psychiatric condition that Drs. Layton or Rodin determine would compromise safe participation.",true,"ALL","18 Years",{"count":20,"type":21},205,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Using a randomized controlled trial (RCT), the goal of this study is to evaluate the ability of evidence based behavioral treatment (contingency management: CM) to significantly decrease alcohol use and cigarette smoking among treatment-seeking smokers with an alcohol use disorder (AUD) who have initiated pharmacotherapy (varenicline; VC) for smoking cessation.",[27,28],"Alcohol Use Disorder (AUD)","Nicotine Use Disorder",[30,31,32,33,28],"Alcohol Use Disorder","Contingency Management","Incentives for Sobriety","Varenicline","RECRUITING","2026-06-30",{"date":37,"type":38},"2026-07-02","ACTUAL",{"date":40,"type":38},"2022-07-11",{"date":42,"type":21},"2027-05-01",{"name":44,"class":45},"Washington State University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":46},"100510923","effects-of-novel-e-cigarette-constituents-on-adults-tcors-30-100510923","NCT05932745","Effects of Novel E-cigarette Constituents on Adults TCORS 3.0","Examining Appeal and Addiction Potential of Novel E-cigarette Constituents Among Adults","Inclusion Criteria:\n\n* 18 years or older\n* Able to read and write\n* Some current e-cigarette use\n* Urine cotinine ≥200ng\u002Fml\n* Willing to abstain from tobacco\u002Fnicotine use 2 hours prior to sessions\n\nExclusion Criteria:\n\n* Current use of non-prescription substances besides nicotine, marijuana, alcohol\n* Any significant current medical or psychiatric condition\n* Known hypersensitivity to propylene glycol\n* Pregnant or lactating females\n* Uncontrolled asthma\n* Nut\u002Fe-liquid flavorant allergy\n* Current marijuana (tetrahydrocannabinol) vaping + E-cigarette or vaping use Associated Lung Injury (EVALI) symptoms\n* Dislike of menthol flavor",{"count":55,"type":21},66,[57],"NA","This study is an examination of the influence of cooling components of WS-3, WS-23, and menthol on the appeal and addiction potential of nicotine-containing e-liquids among adults.",[28],[61],"Menthol, cooling components, cigarette, e-cigarette, vaping","2026-06-12",{"date":64,"type":38},"2026-06-16",{"date":66,"type":38},"2025-06-20",{"date":68,"type":21},"2026-08",{"name":70,"class":45},"Yale University",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":46},"100580432","implementation-of-tobacco-cessation-programming-at-community-behavioral-health-sites-100580432","NCT06837220","Implementation of Tobacco Cessation Programming at Community Behavioral Health Sites","Enhancing the Implementation of Tobacco Treatment: A Community-responsive Approach","Inclusion Criteria:\n\n* Identify as someone who currently smokes combustible cigarettes (at least 1 cigarette per day) on each day for the past month\n* Report interest in quitting cigarettes (at least 6\u002F10 scale in interest of quitting)\n* Age 18 or older, ability to understand the English language, willing and able to provide informed consent\n* Stable residence and contact information throughout the follow up period\n\nExclusion Criteria:\n\n* Non-daily or intermittent cigarette use\n* No interest in quitting smoking\n* Unstable residence\u002Fnot staying in Chicago for duration of study period\n* Current untreated severe substance use disorder (with the exception of tobacco use) or past-year serious untreated psychiatric illness (e.g. schizophrenia, bipolar disorder, obsessive compulsive disorder, unspecified psychosis, past-year suicide attempt)","26 Years",{"count":80,"type":21},24,[57],"The goal of this study is to: partner with Respiratory Health Association and determine barriers and unmet smoking cessation treatment needs from leaders in behavioral health organizations, treatment programs and adults who smoke (AWS) in Chicago. This will be accomplished by establishing a community advisory board (CAB) and pilot testing a community-informed smoking cessation treatment within a community behavioral health organization to determine its feasibility after addressing implementation issues.",[28,84,85],"Smoking Cessation","Smoking Cessation Intervention",[87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113],"smoking","smoking cessation","nicotine","nicotine use disorder","quitting smoking","quitting nicotine","respiratory health","telehealth","virtual","tobacco","tobacco treatment","community","behavioral health","chicago","group therapy","disparities","adults who smoke","cigarettes","tobacco cessation","cessation","abstinence","substance use","substance abuse","addiction","counseling","health counseling","health communication","2026-04-09",{"date":116,"type":38},"2026-04-14",{"date":118,"type":21},"2026-05",{"date":120,"type":21},"2026-11",{"name":122,"class":45},"University of Chicago",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":129,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":46},"100515646","phase-1-testing-the-feasibility-and-acceptability-of-social-media-and-digital-therapeutics-to-decrease-vaping-behaviors-100515646","NCT05994209","Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vaping Behaviors","Inclusion Criteria:\n\n* US Resident\n* English Speaking\n* Have daily access to a smartphone\n* Current vaping product user (P30D)\n* Identified as socially networking about a desire to quit vaping and\u002For experiencing negative health outcomes due to vaping\n* Vaping product user only (i.e., not using vaping as a means to support combustible smoking cessation)","15 Years","25 Years",{"count":132,"type":21},189,[134],"PHASE1","Use of vaping products (e.g., electronic nicotine delivery systems, e-cigarettes) has been increasing rapidly, particularly among teens and young adults. With limited information on the long-term effects of vaping products, health information about vaping has been somewhat unclear in regards to associated health risks. Teens and young adults may be reluctant to disclose their use of vaping products to parents or health providers and instead turn to social media to share and seek out information regarding vaping risks and cessation supports. Thus, our current proposal outlines the use of social media to identify teens and young adults socially networking about vaping, the use of an online chatbot screen to evaluate individual cessation support needs, and the use of a digital intervention system to support vaping cessation. The mobile intervention used in this study is based on a widely-used evidence-based mobile intervention for combustible smoking (i.e., quitSTART) and has been adapted for vaping and young adults to include an in-app chatbot to guide users to tailored content and to motivate and encourage their cessation efforts. We aim to integrate our social media recruitment and online screening approach to connect individuals with this mobile app intervention, and will conduct a randomized controlled trial to evaluate user engagement with and preliminary efficacy of the digital intervention on reducing vaping behaviors among teens and young adults.",[137,28],"Nicotine Vaping",[139,140,141,142,143,89,144],"vaping","mobile app intervention","youth","young adults","chatbot","social media","2026-04-07",{"date":147,"type":38},"2026-04-13",{"date":149,"type":38},"2025-06-04",{"date":151,"type":21},"2027-03",{"name":153,"class":45},"Washington University School of Medicine",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":162,"minAge":18,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":168,"conditions":169,"keywords":173,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":46},"100478851","phase-4-smoking-cessation-and-menstrual-cycle-phase-100478851","NCT05515354","Smoking Cessation and Menstrual Cycle Phase","Coordinating Smoking Cessation Treatment With Menstrual Cycle Phase to Improve Quit Outcomes: A Randomized Controlled Trial","MC-NRT","Inclusion Criteria:\n\n* Must provide informed consent following the CAMH REDCap e-consent framework and procedures;\n* Stated willingness to comply with all study procedures;\n* Naturally cycling individuals with regular MCs (defined as length ranging 21 to 35 days over past 6 months);\n* Daily smoker of ≥5 cigarettes per day (CPD) over past 6 months;\n* Intention to quit smoking within the next 30 days and willing to make a quit attempt on their assigned TQD;\n* Interested in using, and able to use, nicotine patches and gum or lozenge as a smoking cessation aid;\n* Willing to provide a valid e-mail address to be used for study communications and to complete online questionnaires.\n\nExclusion Criteria:\n\n* Current use of progesterone, estrogen, testosterone, or fertility treatment;\n* Current use of nicotine replacement therapy or other smoking cessation medications (e.g., varenicline, bupropion);\n* Use of hormonal contraceptives in the past 6 months (e.g., pill, patch, hormonal intrauterine device \\[IUD\\], ring);\n* Pregnancy, or trying to become pregnant in the next 2-3 months;\n* Known hypersensitivity or allergies to any of the components of the nicotine patch;\n* Daily or almost daily use of cannabis in the past 6 months;\n* Daily or almost daily use of tobacco or nicotine products other than cigarettes (e.g., smokeless tobacco, heat-not-burn products, e-cigarettes) in the past 6 months;\n* Polycystic ovary syndrome diagnosis;\n* Unstable psychiatric condition (including substance use disorder) which would compromise study compliance;\n* Life threatening arrhythmias or severe\u002Fworsening angina pectoris;\n* Myocardial infarction or cerebral vascular accident in the past 2 weeks; or\n* Diagnosed with a terminal illness.","FEMALE","40 Years",{"count":165,"type":21},1200,[167],"PHASE4","Tobacco use is a risk factor for at least 20 types of cancer and remains the leading preventable cause of cancer in Canada. Smoking cessation is an important cancer prevention strategy for the close to 2 million Canadian women who currently smoke. However, findings from controlled trials and real-world clinical settings indicate that women have greater difficulty achieving abstinence following a quit attempt than men. There is some evidence that hormonal levels and fluctuations throughout the menstrual cycle (MC) may contribute to the greater difficulty women experience when trying to quit smoking. In this study, the start of a quit attempt using nicotine replacement therapy (NRT) will be targeted to specific phases of MC. It was hypothesized that starting a quit attempt during the first half of MC (follicular phase) will result in increased quit success compared to starting during the second half of MC (luteal phase) or the usual practice of not targeting quit start date to MC phase.",[170,171,84,28,172],"Nicotine Dependence","Tobacco Smoking","Substance Use Disorders",[174,175,176,177,178,179,180,181],"Menstrual Cycle","Ovarian Hormones","Smoking Cessation Treatment","Nicotine Replacement Therapy","Cancer Prevention","Randomized Controlled Trial","Estrogen","Progesterone","2026-03-17",{"date":184,"type":38},"2026-03-19",{"date":186,"type":38},"2022-11-30",{"date":188,"type":21},"2026-12-31",{"name":190,"class":45},"Centre for Addiction and Mental Health",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":16,"sex":17,"minAge":197,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":22,"phases":201,"briefSummary":202,"conditions":203,"keywords":204,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":46},"100609108","temporal-interference-methods-for-addiction-treatment-100609108","NCT07210268","Temporal Interference Methods for Addiction Treatment","Inclusion Criteria:\n\n* Between the ages of 21 and 50\n* Nicotine dependent and vape at least 15 mg nicotine per day\n* Must have a phone with internet access\n* Participants must have at least a 6th grade education and be able to speak and read English\n\nExclusion Criteria:\n\n* History of seizures, seizure disorders, or familial history of seizure disorders\n* History of intractable migraine or complicated migraine syndromes\n* History of suicide attempts or active suicidal ideation (past month)\n* History of cardiac arrhythmias, prolonged QT, pacemakers, or cardiovascular disorders\n* Hypertension with systolic BP \\>150mmHgCentral nervous system structural lesions (tumors, MS, strokes, etc.)\n* Active neuropsychiatric disorders (schizophrenia, bipolar, active psychosis, dementia, etc.)\n* History of head trauma with loss of consciousness, skull fractures, subdural hematomas\n* Active opioid, cocaine, and\u002For methamphetamine use\n* Active severe cannabis use disorder\n* Active alcohol use disorder or history of alcohol withdrawal\n* Metal implants in the head or under the scalp (excluding dental implants)\n* Current smoking cessation treatment or medications affecting reward processing\n* Pregnancy","21 Years","50 Years",{"count":200,"type":21},120,[57],"This clinical study is testing whether a new non-invasive brain stimulation method, called temporal interference (TI), can reduce nicotine cravings and usage in people who vape. TI delivers mild electrical currents to the scalp in a way that targets deep brain areas involved in addiction, without the need for surgery.\n\nIn this randomized controlled trial, participants will be assigned to one of three groups: TI stimulation to the nucleus accumbens, TI stimulation to the anterior insula, or a placebo (sham) condition. Each participant will attend a single stimulation session after 8 hours of nicotine abstinence and will use a custom vape device that measures real-time nicotine inhalation. Craving levels will be reported during and after the session.\n\nThe study aims to determine whether TI to the insula or nucleus accumbens is more effective at decreasing cravings and nicotine inhalation, and whether either is more effective than sham stimulation. For one week after the session, participants will use a smartphone app to track nicotine use and cravings. The primary hypothesis is that TI stimulation to deep brain regions will reduce both nicotine craving and actual use, immediately after stimulation and over the following week, compared to the sham condition.",[28,172],[205,206,172,207,208],"Nicotine Addiction","Non-invasive deep brain stimulation","Temporal Interference Stimulation","BOLD Activation","2026-02-06",{"date":211,"type":38},"2026-02-10",{"date":213,"type":38},"2026-01-22",{"date":215,"type":21},"2027-02-27",{"name":217,"class":45},"Indiana University",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":225,"enrollmentInfo":226,"targetDuration":4,"studyType":22,"phases":228,"briefSummary":229,"conditions":230,"keywords":231,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":46},"100569564","identify-the-optimal-tms-pulse-protocol-to-modulate-reward-activity-100569564","NCT06695884","Identify the Optimal TMS Pulse Protocol to Modulate Reward Activity","Determining the Optimal Pulse Protocol for TMS Induced Change in Reward Positivity","Inclusion Criteria:\n\n1. Nicotine dependent individuals (according to the Alcohol, Smoking and Substance Involvement Screening Test nicotine dependence score).\n2. Be between the ages of 18 and 55 years old.\n3. Not received substance abuse treatment within the previous 30 days.\n4. Be in stable mental and physical health.\n5. If female, test non-pregnant.\n6. No evidence of focal or diffuse brain lesion on MRI.\n7. Be willing to provide informed consent.\n8. Be able to comply with protocol requirements and likely to complete all study procedures.\n\nExclusion Criteria:\n\n1. Contraindication to MRI (e.g., presence of metal in the skull, orbits or intracranial cavity, claustrophobia).\n2. Contraindication to rTMS (history of neurological disorder or seizure, increased intracranial pressure, brain surgery, or head trauma with loss of consciousness for \\> 15 minutes, implanted electronic device, metal in the head, or pregnancy).\n3. History of autoimmune, endocrine, viral, or vascular disorder affecting the brain.\n4. History or MRI evidence of neurological disorder that would lead to local or diffuse brain lesions or significant physical impairment.\n5. Life time history of mental disorders such as: Bipolar Affective disorder (BPAD), Schizophrenia, Post-traumatic Stress disorder (PTSD) or Dementia or Major Depression.\n6. uninterruptable central nervous system medication","55 Years",{"count":227,"type":21},42,[57],"The primary goal will be to identify the optimal pulse protocol by systematically measuring the efficacy of various theta burst stimulation and repetitive rTMS protocols to increase and decrease the reward positivity in dependent smokers. The secondary objective will be to measure the protocols' effectiveness to increase decision-making capacity using the probabilistic selection task (PST). The third objective will be to specifically assess whether the TMS targets has a differential impact on state levels of craving relative to baseline (Tobacco Craving Questionnaire \\[TCQ\\]. The investigators plan to accomplish these three objectives using a randomized, controlled experiment involving 2 sessions.",[28],[232,233,234,87],"transcranial magnetic stimulation","reward processing","EEG","2025-11-14",{"date":237,"type":38},"2025-11-18",{"date":239,"type":38},"2024-08-01",{"date":241,"type":21},"2026-08-31",{"name":243,"class":45},"Rutgers, The State University of New Jersey",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":225,"enrollmentInfo":251,"targetDuration":4,"studyType":22,"phases":253,"briefSummary":254,"conditions":255,"keywords":256,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":46},"100498130","identify-the-optimal-tms-target-to-modulate-reward-activity-100498130","NCT05766254","Identify the Optimal TMS Target to Modulate Reward Activity","Identify the Optimal TMS Target to Modulate Midcingulate Reward Activity in Smokers","Inclusion Criteria:\n\n1. Nicotine dependent individuals (according to the Alcohol, Smoking and Substance Involvement Screening Test nicotine dependence score).\n2. Be between the ages of 18 and 55 years old.\n3. Not received substance abuse treatment within the previous 30 days.\n4. Be in stable mental and physical health.\n5. If female, test non-pregnant.\n6. No evidence of focal or diffuse brain lesion on MRI.\n7. Be willing to provide informed consent.\n8. Be able to comply with protocol requirements and likely to complete all study procedures.\n\nExclusion Criteria:\n\n1. Contraindication to MRI (e.g., presence of metal in the skull, orbits or intracranial cavity, claustrophobia).\n2. Contraindication to rTMS (history of neurological disorder or seizure, increased intracranial pressure, brain surgery, or head trauma with loss of consciousness for \\> 15 minutes, implanted electronic device, metal in the head, or pregnancy).\n3. History of autoimmune, endocrine, viral, or vascular disorder affecting the brain.\n4. History or MRI evidence of neurological disorder that would lead to local or diffuse brain lesions or significant physical impairment.\n5. Life time history of mental disorders such as: Bipolar Affective disorder (BPAD), Schizophrenia, Post-traumatic Stress disorder (PTSD) or Dementia or Major Depression.\n6. uninterruptable central nervous system medication",{"count":252,"type":21},36,[57],"Our primary goal will be to identify the optimal prefrontal-cingulate target by systematically measuring the efficacy of various image-based targeting techniques to increase the reward positivity using the 10-Hz TMS protocol in dependent smokers. Our secondary objective will be to measure the targets' effectiveness to increase decision-making capacity using the probabilistic selection task (PST). Our third objective will be to specifically assess whether the TMS targets has a differential impact on state levels of craving relative to baseline (Tobacco Craving Questionnaire \\[TCQ\\]. We plan to accomplish these three objectives using a randomized, controlled experiment involving 3 sessions.",[28],[232,233,234,257],"neuroimaging",{"date":259,"type":38},"2025-11-17",{"date":261,"type":38},"2023-03-24",{"date":263,"type":21},"2026-09",{"name":243,"class":45},{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":272,"enrollmentInfo":273,"targetDuration":4,"studyType":22,"phases":275,"briefSummary":276,"conditions":277,"keywords":279,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":46},"100577440","phase-4-tdcs-plus-varenicline-for-smoking-cessation-100577440","NCT06798324","tDCS Plus Varenicline for Smoking Cessation","Using Non-Invasive Brain Stimulation (tDCS) as an Adjunct to Varenicline for the Treatment of Tobacco Dependence: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Be able to provide informed written consent\n* Stated willingness to comply with all study procedures\n* Age 18-85 years\n* Smoke ≥ 8 cigarettes per day (CPD)\n* Is seeking treatment for tobacco dependence\n* Willing to attend the required clinic appointments (Two consecutive weeks, Monday through Friday)\n* Otherwise healthy (i.e. not suffering from any major illness\u002Fcondition that would impact their participation in the study)\n\nExclusion Criteria:\n\n* Use of smoking cessation medication (e.g. buproprion, varenicline, NRT, cytisine) in the past 3 months\n* Current regular use of nicotine-containing products besides cigarettes (e.g. electronic cigarettes, etc.)\n* Unstable psychiatric illness that would adversely impact study participation and compliance (determined by the QI)\n* History of seizures\u002Fepilepsy\n* Lifetime history of concussions or head traumas\n* Current pregnancy or plans to become pregnant\n* Current pacemakers or implanted electrical devices\n* Current metal embedded in the skull\n* Presence of skin lesions, open wounds, or bruising at stimulation sites; or\n* Contraindications to varenicline use (e.g. pregnant\u002Fbreastfeeding, alcohol dependence, kidney disease\u002Frenal impairment, known hypersensitivity to varenicline)","85 Years",{"count":274,"type":21},160,[167],"The goal of this clinical trial is to determine if active transcranial direct current stimulation (tDCS) plus varenicline is an effective, safe and accessible treatment option for smoking cessation. The main questions this trial aims to answer are:\n\n1. Does active tDCS plus varenicline improve short-term and long-term smoking abstinence rates compared to sham tDCS plus varenicline?\n2. Are the safety profiles between active tDCS plus varenicline and sham tDCS plus varenicline different?\n\nThe tDCS treatment schedule includes 10 daily sessions for the first 2 weeks (M to F), followed by 5 single bi-weekly booster sessions for the remainder of the treatment period. Participants will come in-person for two follow-up sessions to assess smoking behaviour at 6- and 12-months post-treatment.",[170,171,84,28,278,172],"Tobacco Use Disorder",[280,278,84,172,281,282,283,284,33],"Smoking","Brain Stimulation","Transcranial Direct Current Stimulation","Tobacco Cigarettes","tDCS","2025-08-07",{"date":287,"type":38},"2025-08-12",{"date":289,"type":38},"2025-03-10",{"date":291,"type":21},"2028-08-01",{"name":190,"class":45},{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":300,"enrollmentInfo":301,"targetDuration":4,"studyType":22,"phases":303,"briefSummary":304,"conditions":305,"keywords":306,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":46},"100557895","real-time-ecounselling-for-nicotine-addiction-100557895","NCT06544057","Real-time eCounselling for Nicotine Addiction","Real-time eCounselling for Nicotine Addiction: a Feasibility Study and Pilot RCT","Inclusion Criteria:\n\n1. Age: 18-65 Years old\n2. Self Reported smoking ≥ 5 cigarettes per day, or regular vaper of \\> 0mg nicotine\n3. Desire to quit nicotine consumption\n4. Willing to set a quit date\n5. Able to provide written informed consent to participate -\n\nExclusion Criteria:\n\n1. Enrolled in another behavioural intervention programme\n2. Pregnant, breastfeeding or planning to become pregnant.\n3. Individuals currently experiencing a problematic relationship with alcohol or drugs\n4. Documented Cognitive Impairment\n5. Individuals with a PHQ-9 score of ≥ 14 or a GAD-7 score of \\>12.","65 Years",{"count":302,"type":21},60,[57],"The goal of this clinical trial is to pilot an eHealth intervention (real-time telecounselling) in nicotine addiction. The main questions it aims to answer are:\n\nIs the intervention likely to be efficacious in preventing an increase in Abstinence? Is the intervention likely to be efficacious in preventing an increase in nicotine consumption? Is the intervention likely to be efficacious in influencing Readiness to quit nicotine? How feasible is the intervention for developing a larger-scale trial?\n\nResearchers will compare a range of outcome measures between the active and control arms, to see if a pilot eHealth intervention can successfully treat nicotine addiction.",[28],[307,308,309,310,311,312],"Smoking cessation","Vaping","Public health","eHealth","Nicotine addiction","Feasibility","2024-11-27",{"date":315,"type":38},"2024-11-29",{"date":317,"type":38},"2024-07-08",{"date":319,"type":21},"2025-01-30",{"name":321,"class":45},"Overcome"]